

Edgar Filing: DRAGON PHARMACEUTICAL INC - Form 8-K

DRAGON PHARMACEUTICAL INC
Form 8-K
March 02, 2005

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 8-K

Current Report

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 1, 2005

DRAGON PHARMACEUTICAL INC.
(Exact name of registrant as specified in its charter)

Florida ----- (State or Other Jurisdiction of Incorporation)	0-27937 ----- (Commission File Number)	65-0142474 ----- (IRS Employer Identification No.)
-----------------------------------------------------------------------	----------------------------------------------	-------------------------------------------------------------

1055 Hastings Street, Suite 1900
Vancouver, British Columbia

(Address of Principal Executive Offices)

V6E 2E9

(Zip Code)

(604) 669-8817

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Section 9 - Financial Statements and Exhibits

The Registrant is filing certain agreements previously entered into and that are part of the Registrant's and Oriental Wave Holding Limited's business.

Item 9.01 Financial Statements and Exhibits

Edgar Filing: DRAGON PHARMACEUTICAL INC - Form 8-K

(c) Exhibits

Exhibit No.	Exhibit Description
-----	-----
10.18*	Collaboration Agreement among Transworld Pharmaceuticals Corporation Inc., Toray Trading Corp. and Dragon Pharmaceutical Inc., effective as of April 30, 2001.
10.19*	Agent Agreement among Allwin Biotrade, Inc., Jiangsu Wuzhong Industry Co. Ltd. and Jiangsu Wuzhong Industry Co. Ltd. Suzhou Zhongkai Bio-Pharmaceuticals Plant, effective as of March 12, 2004.
10.20*	Development and Manufacturing Agreement between Dragon Pharmaceutical Inc. and Polymun Scientific Immunbiologische Forschung GmbH, effective as of October 31, 2003.
10.21*	Agreement for Advance and Long Term Supply of Products by and between Aurobindo (Datong) Bio-Pharma Co. Ltd. and Shanxi Weiqida Pharmaceutical Co. Ltd., dated March 25, 2004.
10.22*	Technology Transfer Agreement between Shanxi Weiqida Pharmaceutical Co. Ltd and Alpha Process Trust Reg., effective as of August 6, 2002.
10.23*	Manufacturing Agreement for Dry-freeze Levofloxacin Injectable by and between Shanxi Weiqida Pharmaceutical Co., Ltd. and Shanxi Pude Pharmaceutical Co., Ltd., effective as of April 21, 2003.
10.24*	Technology Transfer Agreement between Shanxi Weiqida Pharmaceutical Co. Ltd and Alpha Process Trust Reg., effective as of April 18, 2002.

* Confidential treatment requested as to certain portions, which portions are omitted and filed separately with the Securities and Exchange Commission.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: March 1, 2005

DRAGON PHARMACEUTICAL INC.

/s/ Maggie Deng

Maggie Deng
Chief Operating Officer